

IL-17A [Biotinylated]:IL-17RA Inhibitor Screening ELISA Kit

Pack Size: 96 tests

Catalog Number: EP-139

IMPORTANT: Please carefully read this manual before performing your experiment.

For Research Use Only. Not For Use In Diagnostic Or Therapeutic Procedures

HTTP://WWW.ACROBIOSYSTEMS.COM



INTENDED USE

This kit is designed for screening of inhibitors of binding between human IL-17A and human IL-17RA. It is intended for research use only (RUO).

PRINCIPLE OF THE ASSAY

This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new IL-17A pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human IL-17A to immobilized human IL-17RA in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Biotinylated IL-17A protein, a human IL-17RA protein, an anti-IL-17A neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent. Your experiment will include 4 simple steps:

1) Coat the plate with human IL-17RA.

2) Add your molecule of interest to the tests.

3) Add human IL-17A-Biotin to bind the coated human IL-17RA.

4) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.

Finally, the half maximal inhibitory concentration (IC50) of your compound to IL-17A: IL-17RA binding will be determined by comparing OD readings among different experimental groups.

MATERIALS PROVIDED

TABLE 1. MATERIALS PROVIDED (pls modify according to COA)

Asia and Pacific:



Catalog	Components	Size (96 tests)	Format	Storage	
EP139-C01	High-bind Plate	1 plate	Solid	2-8°C	
EP139-C02	Human IL-17RA	15 µg	Powder	2-8°C	-70°C after
EP139-C03	Biotinylated Human IL-17A	10 µg	Powder	2-8°C	reconstitution, avoid
EP139-C04	Anti-IL-17A Neutralizing Antibody	20 µg	Powder	2-8°C	freeze-thaw cycles
EP139-C05	Streptavidin-HRP	10 µg	Powder	2-8°C, avoid light	neeze maw cycles
EP139-C06	Coating Buffer	12 mL	Liquid	2-8°C	
EP139-C07	10xWashing Buffer	50 mL	Liquid	2-8°C	
EP139-C08	Blocking Buffer	50 mL	Liquid	2-8°C	
EP139-C09	Substrate Solution	12 mL	Liquid	2-8°C, avoid light	
EP139-C10	Stop Solution	7 mL	Liquid	2-8°C	

REAGENTS/EQUIPMENT NEEDED BUT NOT SUPPLIED

Single or dual wavelength microplate reader with 450 nm/630nm filter ;

Centrifuge;

37 °C Incubator;

Single channel or multichannel pipettes with 10 $\mu L, 200 \; \mu L$ and 1000 μL precision ;

10 $\mu L,$ 200 μL and 1000 μL pipette tips ;

Test Tubes;

Graduated cylinder;

Deionized or distilled water for dilution ;

STORAGE AND VALIDITY INSTRUCTIONS

Unopened kit should be stored at 2°C -8°C upon receiving. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

The kit should be stored as TABLE 1 after the reconstitution of lyophilized materials. The shelf life is 30 days from the date of opening.



Note:

a. Do not use reagents past their expiration date.

b. Find the expiration date on the outside packaging.

REAGENT PREPARATION

1. Restore all reagents and samples to room temperature (20-25°C) before use.

2. Reconstitute the provided lyophilized materials to stock solutions with sterile deionized water as recommended in

Tab.2, Solubilize for 15 to 30 minutes at room temperature with occasional gentle mixing. Avoid vigorous shaking or

vortex. The reconstituted stock solutions should be stored at -70°C. Avoid freeze-thaw cycles.

Note: Streptavidin-HRP stock solution should be protected from light.

TABLE 2. RECONSTITUTION METHODS FOR 96 TESTS

Catalog	Components	Amount	Stock Solution Con.	Reconstitution Buffer and Vol.
EP139-C02	Human IL-17RA	15 µg	100 μg/mL	150 μL, water
EP139-C03	Biotinylated Human IL-17A	10 µg	50 µg/mL	200 µL, water
EP139-C04	Anti-IL-17A Neutralizing Antibody	20 µg	100 μg/mL	200 µL, water
EP139-C05	Streptavidin-HRP	10 µg	50 µg/mL	200 µL, water

RECOMMENDED PROTOCOL

1. Working solution preparation

1.1 Preparation of 1×Washing Buffer:

Dilute 50 mL 10×Washing Buffer with ultrapure water/deionized water to 500 mL.

1.2 Preparation of Dilution Buffer:

10 mL Blocking Buffer (EP139-C08) add 30 mL 1×Washing Buffer.

2. Coating

1)Dilute Human IL-17RA stock solution (100 µg/mL) to 1 µg/mL with Coating Buffer to make Human IL-17RA

working solution.

2)Add 100 μ L of Human IL-17RA working solution (1 μ g/mL) to each well and leave a couple of wells uncoated for

Web: http://www.acrobiosystems.com



No-Coating Control, seal the plate with microplate sealing film and incubate overnight (or 16 hours) at 4°C.

3. Washing

Remove the remaining solution by aspiration, add 300 μ L of 1×Washing Buffer to each well, gently tap the plate for 1 minute, remove any remaining 1×Washing Buffer by aspirating or decanting, invert the plate and blot it against paper towels. Repeat the washing step above for three times.

Note: For best results, the complete removal of the Human IL-17RA solution is essential. The use of a manifold dispenser or an autowasher may be necessary.

4. Blocking

Add 300 µL Blocking Buffer to each well, seal the plate with microplate sealing film and incubate at 37 °C for 1.5 hours.

5. Washing

Repeat step 3. At the same time, you can start to prepare your samples.

6. Add Samples

1)Make serial dilution of the samples as appropriate.

2)If you intend to use the provided Anti-IL-17A Neutralizing Antibody as a reference (Std.), you may dilute the antibody as recommended in Figure 1.

3)Add 50 µL of sample solution to each well according to our recommendation (Figure 2) or your own plate setup.

4)For No-Coating Control wells, please add 50 µL Dilution Buffer.

7.Binding

1) Dilute Biotinylated Human IL-17A stock solution (50 μ g/mL) to 0.1 μ g/mL with Dilution Buffer to make

Biotinylated Human IL-17A working solution.

2) For No-binding control wells, please add 50 μL Dilution Buffer.

3) For all other wells, please add 50 μL Biotinylated Human IL-17A working solution to the wells and mix the

samples by gently tapping the plate. Seal the plate with microplate sealing film and incubate at 37°C for 1 hour.

Note: The working solution should be prepared immediately before use and should not be stored.

FIG.1 PREPARATION OF 1:1 SERIAL DILUTIONS OF THE Anti-IL17A Neutralizing Antibody







FIG.2 PLATE LAYOUT



8.Washing

Repeat step 3.

9.Add Streptavidin-HRP

1)Dilute Streptavidin-HRP stock solution (50 µg/mL) to 0.1 µg/mL with Dilution Buffer to make Streptavidin-HRP

working solution.

2)For all wells, add 100 µL Streptavidin-HRP working solution, seal the plate with microplate sealing film and incubate at 37°C for 1 hour, avoid light.

10.Washing

Repeat step 3.

US and Canada:

Web: http://www.acrobiosystems.com



11.Substrate Reaction

Add 100 µL Substrate Solution to each well. Seal the plate with microplate sealing film and incubate at 37°C for

20 minutes. Avoid light.

12.Termination

Add 50 µL Stop Solution to each well, and gently shake the plate to allow thorough mixing.

Note: the color in the wells should change from blue to yellow.

13.Data Recording

Read the absorbance at 450 nm using UV/Vis microplate spectrophotometer.

Note: Subtracting the value read at OD_{450nm} with OD_{630nm} can be used to reduce the background noise.

SIMPLIFIED PROTOCOL

Steps Code	Steps	Reagents & Instruments	Reaction Conditions	Samples	No-binding Ctrl.	No-coating Ctrl.	Positive Ctrl.
1	Working fluid preparation	N/A	N/A	N/A	N/A	N/A	N/A
2	Coating	Human IL-17RA Working Solution	4°C for overnight	100 µL	100 µL		100 µL
3	Washing	1XWash Buffer	Wash for 3 times	300 µL	300 µL	300 µL	300 µL
4	Blocking	Blocking Buffer	37°C for 1.5 hours	300 µL	300 µL	300 µL	300 µL
5	Washing	1XWash Buffer	Wash for 3 times	300 µL	300 µL	300 µL	300 µL
	A 11 G 1	Samples		50 µL			_
6	Add Samples	Dilution Buffer			50 µL	50 µL	50 µL
7	Binding	Biotinylated Human IL-17A Working Solution	Mix by gentle tapping, incubate at 37°C for 1	50 µL	_	50 µL	50 µL
		Dilution Buffer	hours		50 µL		—
8	Washing	1XWash Buffer	Wash for 3 times	300 µL	300 µL	300 µL	300 µL
9	Streptavidin-HRP	Streptavidin-HRP Working Solution	37°C for 1 hours	100 µL	100 µL	100 µL	100 µL

TABLE. 3 ASSAY PROTOCOL

US and Canada:

Tel: +1 800-810-0816

Web: <u>http://www.acrobiosystems.com</u>

7 /9

Asia and Pacific:

Tel: +86 400-682-2521

E-mail: order@acrobiosystems.com



10	Washing	1XWash Buffer	Wash for 3 times	300 µL	300 µL	300 µL	300 µL
11	Substrate Reaction	Substrate Solution	37°C for 20 minutes	100 µL	100 µL	100 µL	100 µL
12	Termination	Stop Solution	Mix by gentle tapping	50 µL	50 µL	50 µL	50 µL
13	Data Recording	UV/Vis spectrophotometer	Measure absorbance at 450 nm, with the correction wavelength set at 630 nm				

Note for TAB. 3:

- 1) Samples: Your samples of interest.
- 2) No-binding Ctrl.: Reaction without Biotinylated Human IL-17A added. The absorbance should be around 0.05(< 0.1) at 450 nm.
- 3) No-coating Ctrl.: Reaction without Human IL-17RA coated on the wells. The absorbance should be around 0.05 (< 0.1) at 450 nm.
- *4) Positive Ctrl.*: *Determined the max value in 450nm absorbance, when out of inhibitors.*
- 5) It is recommended that all samples, controls and standards should be done in duplicates.

PRECAUSIONS

- 1. This kit is for research use only and is not for use in diagnostic or therapeutic applications.
- 2. This kit should be used according to the provided instructions.
- 3. Do not mix reagents from different lots.
- 4. All reagents should be balanced to room temperature (20°C-25°C) before use.
- 5. This kit should be stored at 2°C-8°C.
- 6. Please prepare the working solution of each component according to the needs of the experiment. Except for


1x Washing Buffer, all prepared working solution is for one-time use and cannot be stored.

METHOD VERIFICATION

INHIBITION OF IL-17A[Biotinylated]: IL-17RA BINDING BY ANTI-IL-17A NEUTRALIZING ANTIBODY

Serial dilutions of Anti-IL-17A Neutralizing antibody (Catalog # EP139-C04) (1:1 serial dilution, from 10 μ g/mL to 0.01 μ g/mL) was added into Biotinylated IL-17A: IL-17RA binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting.





Anti-IL-17A Neutralizing Antibody Conc.(µg/ml)	Anti-IL-17A Neutralizing Antibody Conc.(nM)	Mean Abs.(OD450)	Percentage Activity(%)
0	0.000	2.493	100%
0.010	0.065	2.52	101%
0.020	0.130	2.487	100%
0.039	0.260	2.478	99%
0.078	0.521	2.474	99%
0.156	1.042	2.274	<mark>91%</mark>
0.313	2.083	1.796	72%
0.625	4.167	1.075	43%
1.25	8.333	0.615	25%
2.5	16.667	0.348	14%
5	33.333	0.213	9%
10	66.667	0.136	5%
No Coating		0.063	
No Binding		0.053	

US and Canada:

Tel: +1 800-810-0816

Asia and Pacific:

Tel: +86 400-682-2521

Web: http://www.acrobiosystems.com

9 /9

E-mail: order@acrobiosystems.com